The fibroblast growth factor receptor (FGFR) inhibitor erdafitinib (Balversa, Janssen) showed promising antitumor activity in patients with advanced urothelial carcinoma with alterations in the FGFR3 gene, yield-ing a 40% overall response rate (ORR), during an open-label, phase 2 trial.
During the trial, an international group of investigators evaluated 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma who had disease progression on or after at least one